Literature DB >> 1108824

Propranolol as primary therapy for thyrotoxicosis.

E L Mazzaferri, J C Reynolds, R L Young, C N Thomas, A F Parisi.   

Abstract

It has been suggested that propranolol hydrochloride alone is effective in the treatment of thyrotoxicosis. To test this hypothesis, eight mildly thyrotoxic individuals were prospectively studied for an average of eight months, during which propranolol alone was administered and thyroid function tests, cardiac systolic time intervals, and body densities were sequentially measured. Two patients became euthyroid. The others had adequate but incomplete symptomatic control. Weight loss was not corrected, but no changes in lean body mass were induced. The augmented myocardial contractility of thyrotoxicosis, as determined by systolic time intervals, improved but failed to return completely to normal. Thus, systolic time intervals are a practical means of following the peripheral response to chronic beta-adrenergic blockage in thyrotoxic patients. However, these observations do not support the use of propranolol alone as the first choice of therapy for thyrotoxicosis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1108824

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  5 in total

1.  Hyperthyroidism and the heart.

Authors:  T J Wilkin
Journal:  Br Med J (Clin Res Ed)       Date:  1983-05-07

Review 2.  Use of beta-adrenoceptor blocking drugs in hyperthyroidism.

Authors:  J Feely; N Peden
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

3.  Effect of timolol on clinical features and echocardiographic assessment of left ventricular function in hyperthyroidism.

Authors:  B E Griffiths; F M Creagh; J H Lazarus; R John; S Kadury
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

4.  Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study.

Authors:  Simon H S Pearce; Colin Dayan; David C Wraith; Kevin Barrell; Natalie Olive; Lotta Jansson; Terrie Walker-Smith; Christina Carnegie; Keith F Martin; Kristien Boelaert; Jackie Gilbert; Claire E Higham; Ilaria Muller; Robert D Murray; Petros Perros; Salman Razvi; Bijay Vaidya; Florian Wernig; George J Kahaly
Journal:  Thyroid       Date:  2019-06-13       Impact factor: 6.568

5.  Adjuvant Rituximab-Exploratory Trial in Young People With Graves Disease.

Authors:  Tim D Cheetham; Michael Cole; Mario Abinun; Amit Allahabadia; Tim Barratt; Justin H Davies; Paul Dimitri; Amanda Drake; Zainaba Mohamed; Robert D Murray; Caroline A Steele; Nicola Zammitt; Sonya Carnell; Jonathan Prichard; Gillian Watson; Sophie Hambleton; John N S Matthews; Simon H S Pearce
Journal:  J Clin Endocrinol Metab       Date:  2022-02-17       Impact factor: 5.958

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.